Injectsense announces first human implant of ultraminiature IOP sensor

News
Article

Injectsense's future plans for the sensor are to fine-tune its delivery tool and incorporate a microbattery into the sensor.

IOP detecting sensor and its applicator Image credit: Injectsense

Image credit: Injectsense

Digital health company Injectsense announced that it has successfully completed the first human implant and wireless IOP measurements using its ultraminiature implantable sensor, which has received FDA breakthrough designation.1 The implant procedure was performed during the IOP-Connect system study by Juan Mura, MD, of the Centro de la Vision in Santiago, Chile, according to a news release.

"From a physician's perspective, this is a major step toward understanding IOP fluctuations and providing more effective glaucoma treatment," said Mura in the release. "It's extremely exciting to have a direct path to an implantable sensor that will provide autonomous measurement 24/7."

Injectsense now plans on fine-tuning the delivery tool for the sensor and to incorporate the Injectpower SAS solid-state microbattery into the sensor. This microbattery will allow for autonomous and continuous measurement of IOP from inside the eye, according to the release. The final product platform will then use smart glasses work by patients for a few minutes each week in order to wirelessly recharge the sensor and uploaded sensor-stored data to a smart phone and cloud platform.1

"Although safety is the primary focus of this study, we are also informing our product design to meet the expectations of ophthalmologists across the globe," said Ariel Cao, President/CEO of Injectsense. "We expect these sensors to be easily delivered in the doctor's office."

In November 2023, Injectsense announced that it secured $9.4 million in funding with sister company Injectpower to bring the implantable device into production.2

References:
  1. Injectsense completes first human implantation of its ultraminiaturized intraocular pressure sensor. PR Newswire. News release. August 27, 2024. Accessed August 28, 2024. https://www.prnewswire.com/news-releases/injectsense-completes-first-human-implantation-of-its-ultraminiaturized-intraocular-pressure-sensor-302231827.html
  2. Injectsense and solid-state microbattery partner Injectpower secure $9.4 million for implantable device supply chain and support of clinical studies. Injectsense. News release. November 15, 2023. Accessed August 28, 2024. https://www.injectsense.com/1-7m-sbir-grant
Recent Videos
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
Clark Chang, OD, MSA, MSc, FAAO, discussed the complexities of diagnosing keratoconus in his Rapid Fire presentation given at the American Academy of Optometry 2024 meeting.
Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO, details the ease of genetic testing when diagnosing patients or reassessing a patient's diagnosis.
Gromacki, OD, FAAO, FSLS, emphasizes that corneal GP lenses remain an important part of a contact lens specialist's armamentarium
Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO, discusses diagnostic confusion that can be encountered when identifying macular edema in patients.
Nate Lighthizer, OD, FAAO, overviews a handful of YAG laser procedures in his AAOpt presentation.
Susan Gromacki, OD, MS, FAAO, FSLS, details a panel that provided a complete course on keratoconus.
© 2024 MJH Life Sciences

All rights reserved.